Market capitalization | $699.83m |
Enterprise Value | $419.56m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.57 |
P/S ratio (TTM) P/S ratio | 10.96 |
P/B ratio (TTM) P/B ratio | 1.45 |
Revenue growth (TTM) Revenue growth | 22.14% |
Revenue (TTM) Revenue | $63.88m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
8 Analysts have issued a CureVac N.V. forecast:
8 Analysts have issued a CureVac N.V. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -281 -281 |
7%
7%
|
|
Depreciation and Amortization | 29 29 |
5%
5%
|
|
Stock Compensation | 8.32 8.32 |
14%
14%
|
|
Operating Cash Flow | -290 -290 |
4%
4%
|
|
Investments | 60 60 |
39%
39%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -346 -346 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Head office | Netherlands |
CEO | Alexander Zehnder |
Employees | 1,172 |
Founded | 2020 |
Website | www.curevac.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.